Ardelyx, Inc. (NASDAQ:ARDX) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET
Company Participants
Justin Renz - Chief Financial Officer
Mike Raab - President and Chief Executive Officer
Susan Rodriguez - Chief Commercial Officer
Robert Blanks - Chief Regulatory Affairs and Quality Assurance Officer
Conference Call Participants
Chris Howerton - Jeffrey
Carly Kenselaar - Citi
Joseph Thome - Cowen and Company
Sam Brandeis - Wedbush
Matthew Kaplan - Ladenburg Thalmann
Operator
Good afternoon and welcome to Ardelyx's First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. As a reminder, today's call is being recorded.
I would now like to turn the call over to Justin Renz, Chief Financial Officer of Ardelyx. You may now begin.
Justin Renz
Thank you and good afternoon, everyone and welcome to our first quarter financial results call. During this call, we will refer to the press release we issued earlier today, which is available in the Investors section of the company's website at ardelyx.com.
On the call with me today with prepared remarks are Mike Raab, President and CEO; and Susan Rodriguez, Chief Commercial Officer; Dr. Laura Williams, Chief Medical Officer; Dr. David Rosenbaum, Chief Development Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer, who will join us for the question-and-answer period.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our quarterly report filed on Form 10-Q earlier today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
With that, let me pass the call over to Mike.
Mike Raab
Thank you, Justin and good afternoon, everyone. We're thrilled to provide you an update on what has been a highly productive quarter filled with positive developments on multiple fronts.
2022 is off to a great start. IBSRELA launches underway and progressing well after just a few weeks on the market and for XPHOZAH we welcome the news from the FDA that an advisory committee will be convened to review and advise on the clinical meaningfulness of our data. These are important catalysts which have the potential to significantly build shareholder value in 2022.